Clinical activity of tipifarnib in hematologic malignancies

Bibliography

• END DW: Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs (1999) 17(3):241-258.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. (1999) 17(11):3631-3652.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, OLIFF A: Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin. Cancer Biol. (2000) 10(6):443-452.
   PubMed Web of Science ®Google Scholar
• COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta (1997) 1333(1):F51-F71.
   PubMedGoogle Scholar
• LEBOWITZ PF, PRENDERGAST GC: Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene (1998) 17(11):1439-1445.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC: Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Histol. Histopathol. (2001) 16(1):269-275.
   PubMed Web of Science ®Google Scholar
• ASHAR HR, JAMES L, GRAY K et al.: The farnesyl transferase inhibitor SCH 66336 induces a G2 – > M or G1 pause in sensitive human tumor cell lines. Exp. Cell Res. (2001) 262(1):17-27.
   PubMed Web of Science ®Google Scholar
• END DW, SMETS G, TODD AV et al.: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. (2001) 61(1):131-137.
   PubMed Web of Science ®Google Scholar
• END D, SKRAZT S, DEVINE A et al.: R1155777, a novel imidazole farnesly protein transferase inhibitor (FTI): biochemical and cellular effects of H-RAS and K-RAS dominant systems. Proc. Am. Assoc. Cancer Res. (1998) 39:270.
   Google Scholar
• SKRATZ S, ANGIBAUD P, VENET M et al.: R115777, a novel imidazole farnesyl protein transferase inhibotor (FTI) with potent oral antitumor activity. Proc. Am. Assoc. Cancer Res. (1998) 39:317.
   Google Scholar
• SMETS G, XHONNEUX B, CORNELISSEN F et al.: R115777, a selective farnesyl protein transferase inhibitor (FTI), induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and in LoVo tumor xenografts. Proc. Am. Assoc. Cancer Res. (1998) 39:318.
   Google Scholar
• VENET M, ANGIBAUD P, SANZ G et al.: Synthesis and in vitro structure-activity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors (FTI). Proc. Am. Assoc. Cancer Res. (1998) 39:318.
   Google Scholar
• JAMES GL, GOLDSTEIN JL, BROWN MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. (1995) 270(11):6221-6226.
   PubMed Web of Science ®Google Scholar
• RUSSO P, MALACARNE D, FALUGI C, TROMBINO S, O’CONNOR PM: RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. Int. J. Cancer (2002) 100(3):266-275.
   PubMed Web of Science ®Google Scholar
• YONEMOTO M, SATOH T, ARAKAWA H et al.: A novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Mol. Pharmacol. (1998) 54(1):1-7.
   PubMed Web of Science ®Google Scholar
• RUSSO P, OTTOBONI C, CRIPPA A, RIOU JF, O’CONNOR PM: RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. Int. J. Oncol. (2001) 18(4):855-862.
   PubMed Web of Science ®Google Scholar
• FALUGI C, TROMBINO S, GRANONE P, MARGARITORA S, RUSSO P: Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability. Curr. Cancer Drug Targets (2003) 3(2):109-118.
   PubMed Web of Science ®Google Scholar
• BRITTEN CD, ROWINSKY EK, SOIGNET S et al.: A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. (2001) 7(12):3894-3903.
   PubMed Web of Science ®Google Scholar
• SHARMA S, BRITTEN C, SPRIGGS D et al.: A Phase I and PK study of farnesyl transferase inhibitor L-778, 123 administered as a seven day continuous infusion in combination with paclitaxel. Proc. Am. Soc. Clin. Oncol. (2000) 19:185a.
   Google Scholar
• DOLL RJ, KIRSCHMEIER P, BISHOP WR: Farnesyltransferase inhibitors as anticancer agents: critical crossroads. Curr. Opin. Drug Discov. Devel. (2004) 7(4):478-86.
   PubMed Web of Science ®Google Scholar
• MANNE V, YAN N, CARBONI JM et al.: Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene (1995) 10(9):1763-1779.
   PubMed Web of Science ®Google Scholar
• JABBOUR E, KANTARJIAN H, CORTES J: Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk. Lymphoma (2004) 45(11):2187-2195.
   PubMed Web of Science ®Google Scholar
• LANCET JE LIESVELD JL, LUDLOW J et al.: Effects of farnesyl transferase inibitor R1155777 on hematopoeisis, leukemic cell proliferation, and signaling through the mitogen-activated kinase (MAPK) pathway. Blood (1999) 194:149b.
   Google Scholar
• LIU M, BRYANT MS, CHEN J et al.: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58(21):4947-4956.
   PubMed Web of Science ®Google Scholar
• REICHERT A, HEISTERKAMP N, DALEY GQ, GROFFEN J: Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood (2001) 97(5):1399-1403.
   PubMed Web of Science ®Google Scholar
• PETERS DG, HOOVER RR, GERLACH MJ et al.: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood (2001) 97(5):1404-1412.
   PubMed Web of Science ®Google Scholar
• RANGANATHAN S, MCCAULEY RA, HUDES GR: Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines. Proc. Am. Assoc. Cancer Res. (1999) 40:523.
   Google Scholar
• ROSE WC, LEE FY, FAIRCHILD CR et al.: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. (2001) 61(20):7507-7517.
   PubMed Web of Science ®Google Scholar
• CAMACHO LH, SOIGNET SL, PEZZULLI S et al.: Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:311 (Abstract).
   Google Scholar
• CORTES JE, KURZROCK R, KANTARJIAN HM: Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin. Hematol. (2002) 39(3 Suppl. 2):26-30.
   Google Scholar
• BEAUPRE DM, KURZROCK R: RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. (1999) 17(3):1071-1079.
   PubMed Web of Science ®Google Scholar
• ALMOGUERA C, SHIBATA D, FORRESTER K, MARTIN J, ARNHEIM N, PERUCHO M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1998) 53(4):549-554.
   Google Scholar
• BOS JL: ras oncogenes in human cancer: a review. Cancer Res. (1990) 1550(4):1352.
   Google Scholar
• RODENHUIS S: ras and human tumors. Semin. Cancer Biol. (1992) 3(4):241-247.
   PubMedGoogle Scholar
• SAWYERS CL, MCLAUGHLIN J, WITTE ON: Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. (1995) 181(1):307-313.
   PubMed Web of Science ®Google Scholar
• DENHARDT DT: Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem. J. (1996) 318(Part 3):729-747.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, GIBBS JB: Ras regulatory interactions: novel targets for anti-cancer intervention? Bioessays (1994) 16(3):187-191.
   PubMed Web of Science ®Google Scholar
• KHOSRAVI-FAR R, COX AD, KATO K, DER CJ: Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. (1992) 3(7):461-469.
   PubMedGoogle Scholar
• GELB MH: Protein prenylation, et cetera: signal transduction in two dimensions. Science (1997) 275(5307):1750-1751.
   PubMed Web of Science ®Google Scholar
• MIDGLEY RS, KERR DJ: Ras as a target in cancer therapy. Crit. Rev. Oncol. Hematol. (2002) 44(2):109-120.
   PubMed Web of Science ®Google Scholar
• ADJEI AA: Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. (2001) 93(14):1062-1074.
   PubMed Web of Science ®Google Scholar
• GILLE H, DOWNWARD J: Multiple ras effector pathways contribute to G1 cell cycle progression. J. Biol. Chem. (1999) 274(31):22033-22040.
   PubMed Web of Science ®Google Scholar
• JOHNSON R, SPIEGELMAN B, HANAHAN D, WISDOM R: Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell Biol. (1996) 16(8):4504-4511.
   PubMed Web of Science ®Google Scholar
• SU ZZ, AUSTIN VN, ZIMMER SG, FISHER PB: Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene (1993) 8(5):1211-1219.
   PubMed Web of Science ®Google Scholar
• ZABRENETZKY V, HARRIS CC, STEEG PS, ROBERTS DD: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer (1994) 59(2):191-195.
   PubMed Web of Science ®Google Scholar
• RAK J, MITSUHASHI Y, BAYKO L et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. (1995) 55(20):4575-4580.
   PubMed Web of Science ®Google Scholar
• WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TN et al.: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. (1997) 272(22):14459-14464.
   PubMed Web of Science ®Google Scholar
• DU W, PRENDERGAST GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res. (1999) 59(21):5492-5496.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, OLIFF A: Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin. Cancer Biol. (2000) 10(6):443-452.
   PubMed Web of Science ®Google Scholar
• WEAVER BA, BONDAY ZQ, PUTKEY FR, KOPS GJ, SILK AD, CLEVELAND DW: Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J. Cell Biol. (2003) 162(4):551-563.
   PubMed Web of Science ®Google Scholar
• LANCET JE, KARP JE: Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood (2003) 102(12):3880-3889.
   PubMed Web of Science ®Google Scholar
• JIANG K, COPPOLA D, CRESPO NC et al.: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell Biol. (2000) 20(1):139-148.
   PubMed Web of Science ®Google Scholar
• WANG E, CASCIANO CN, CLEMENT RP, JOHNSON WW: The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. (2001) 61(20):7525-7529.
   PubMed Web of Science ®Google Scholar
• KURZROCK R, KANTARJIAN HM, CORTES JE et al.: Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase I setting. Blood (2003) 102(13):4527-4534.
   PubMed Web of Science ®Google Scholar
• RAPONI M, BELLY R, ATKINS D et al.: Pharmacogenomic analysis reveals signaling pathways modulated by R115777 (Zarnestra) in acute myeloid leukemia. Proc. Am. Soc. Clin. Oncol. (2002) 21:265a.
   Google Scholar
• SEBTI SM, ADJEI AA: Farnesyltransferase inhibitors. Semin. Oncol. (2004) 31(1 Suppl. 1):28-39.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, BRANLE F, DE VALERIOLA D et al.: A Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:80a (Abstract 318).
   Google Scholar
• RAVANDI-KASHANI F, KANTARJIAN H, GARCIA-MANERO G et al.: Farnesyl transferase inhibitor (tipifarnib, Zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Proc. Am. Soc. Clin. Oncol. (2006) 24:351s (Abstract 6557).
   Web of Science ®Google Scholar
• RAO S, CUNNINGHAM D, DE GRAMONT A et al.: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. (2004) 22(19):3950-3957.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, VAN DE VELDE H, KARASEK P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22(8):1430-1438.
   PubMed Web of Science ®Google Scholar
• ZUJEWSKI J, HORAK ID, BOL CJ et al.: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2000) 18(4):927-941.
   PubMed Web of Science ®Google Scholar
• KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical–laboratory correlative trial. Blood (2001) 97(11):3361-3369.
   PubMed Web of Science ®Google Scholar
• PUNT CJ, VAN MAANEN L, BOL CJ, SEIFERT WF, WAGENER DJ: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs (2001) 12(3):193-197.
   PubMed Web of Science ®Google Scholar
• CRUL M, DE KLERK GJ, SWART M et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2002) 20(11):2726-2735.
   PubMed Web of Science ®Google Scholar
• JOHNSTON SR, HICKISH T, ELLIS P et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. (2003) 21(13):2492-2499.
   PubMed Web of Science ®Google Scholar
• CRUL M, DE KLERK GJ, SWART M et al.: Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. Eur. J. Drug Metab. Pharmacokinet. (2002) 27(1):61-65.
   PubMed Web of Science ®Google Scholar
• SEKERES MA, STONE RM: The challenge of acute myeloid leukemia in older patients. Curr. Opin. Oncol. (2002) 14(1):24-30.
   PubMed Web of Science ®Google Scholar
• THIEDE C, STEUDEL C, MOHR B et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood (2002) 99(12):4326-4335.
   PubMed Web of Science ®Google Scholar
• STIREWALT DL, KOPECKY KJ, MESHINCHI S et al.: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 97(11):3589-3595.
   PubMed Web of Science ®Google Scholar
• LANCET JE, RYAN CP, ABBOUD CN et al.: Differences in the expression of signal transduction molecules between normal and leukemic bone marrow. Blood (2002) 98:111a.
   Google Scholar
• LANCET JE, GOTLIBJ, GOJO I et al.: Tipifarnib (ZARNESTRA®) in previously untreated poor-risk AML of the elderly: updated results of a Phase II trial. Blood (2004) 104:249a.
   Web of Science ®Google Scholar
• HAROUSSEAU JL, REIFFERS J, LOWENBERG B et al.: Zarnestra® (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter Phase II study. Blood (2003) 102:176a.
   Web of Science ®Google Scholar
• KARP JE, GOJO I, GREER J et al.: Tipifarnib (Zarnestra, R115777) as maintenance therapy for adults in complete remission (CR) following induction and consolidation therapies for poor-risk acute myeloid leukemia (AML): a Phase II trial. Blood (2005) 104:780a.
   Google Scholar
• RAPONI M, LOWENBERG B, LANCET JE et al.: Identification of molecular predictors of response to ZARNESTRA™ (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood (2004) 104:246a.
   Web of Science ®Google Scholar
• GOEMANS BF, ZWAAN CM, KASPERS GJ et al.: In-vitro cytotoxicity of tipifarnib (ZARNESTRA™) in pediatric AML and ALL samples is independent of RAS mutations. Blood (2004) 104:332a.
   Google Scholar
• KURZOCK R, FENAUX P, RAZA A et al.: High-risk myelodysplastic syndromes (MDS): results of international Phase II study with oral farnesyl transferase inhibitor R115777 (ZARNESTRATM). Blood (2004) 104(11):23a (Abstract 68).
   Google Scholar
• KURZROCK R, ALBITAR M, CORTES JE et al.: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. (2004) 22(7):1287-1292.
   Google Scholar
• KURZROCK R, VERSTOVSEK S, WRIGHT JJ et al.: Alternate week administration of the farnesyl transferase inhibitor tipifarnib (ZARNESTRA™, R115777) in patients with myelodysplastic syndrome: results of a Phase I study. Blood (2005) 106:708a.
   Google Scholar
• CORTES J, ALBITAR M, THOMAS D et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood (2003) 101(5):1692-1697.
   PubMed Web of Science ®Google Scholar
• GOTLIB J, LOH M, LANCET JE et al.: Phase I/II study of tipifarnib (Zarnestra®, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): interim results. Blood (2003) 102: 921a.
   Google Scholar
• MESA R, CAMORIANO J, GEYER S et al.: A Phase II consortium (P2C) trial of R115777 (tipifarnib) in myelofibrosis with myeloid with myeloid metaplasia. Blood (2004) 104:422a.
   Web of Science ®Google Scholar
• HOOVER RR, MAHON FX, MELO JV, DALEY GQ: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 100(3):1068-1071.
   PubMed Web of Science ®Google Scholar
• CORTES J, GARCIA-MANERO G, O’BRIEN S et al.: Phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy. Blood (2004) 104:289a.
   Web of Science ®Google Scholar
• GOTLIB J, MAURO M, O’DWYER M et al.: Tipifarnib (ZARNESTRA®) and imitanib (GLEEVEC®) combination therapy in patients with adavanced chronic myelogenous leukemia (CML): preliminary results of a Phase I study. Blood (2003) 102:909a.
   Google Scholar